Rapport Therapeutics Quarterly Income Statement
NASDAQ: RAPPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rapport Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Rapport Therapeutics generated $0 in revenue, up 0.0% from the same quarter a year earlier. Rapport Therapeutics reported a net loss of $56.6 million, compared with a loss of $26.7 million a year earlier. Diluted earnings per share came in at -$1.19.
Summary generated from market data by MetaCap's automated system. Methodology
Rapport Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 20.00M | — | — | 0 | 0 | — | — | — | — | — | — |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses | 60.81M | 44.22M | 38.51M | 29.99M | 29.50M | 27.11M | 23.52M | 21.64M | 20.80M | 17.09M | 14.79M | 9.56M |
| Research & Development | 51.41M | 32.72M | 30.26M | 22.28M | 22.68M | 19.57M | 17.20M | 15.54M | 15.69M | 12.50M | 11.80M | 7.58M |
| Selling, General & Admin | 9.39M | 11.50M | — | — | 6.82M | 7.54M | — | — | — | — | — | — |
| Operating Income | -60.81M | -24.21M | -38.51M | -29.99M | -29.50M | -27.11M | -23.52M | -21.64M | -20.80M | -17.09M | -14.79M | -9.56M |
| Other Income (Expense) | 4.19M | 4.36M | 4.75M | 3.06M | 2.76M | 3.04M | 3.54M | 4.10M | 2.68M | -5.58M | 1.28M | 856.00K |
| Pretax Income | — | — | — | — | — | — | -19.98M | -17.54M | -18.12M | — | -13.51M | -8.71M |
| Income Tax | — | — | — | — | — | — | — | — | — | — | 6.00K | 1.00K |
| Net Income | -56.62M | -19.86M | -33.76M | -26.93M | -26.73M | -24.06M | -19.98M | -17.54M | -18.12M | -22.67M | -13.52M | -8.71M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.19 | -0.42 | -0.72 | -0.71 | -0.75 | -0.68 | 9.49 | -0.50 | -1.70 | -11.07 | — | -5.70 |
| EPS (Diluted) | -1.19 | -0.42 | -0.72 | -0.71 | -0.75 | -0.68 | 9.49 | -0.50 | -1.70 | -11.07 | — | -5.70 |
| Shares Outstanding (Basic) | 47.47M | 47.24M | — | 37.93M | 35.44M | 35.27M | — | 34.86M | 10.67M | 2.05M | — | 1.53M |
| Shares Outstanding (Diluted) | 47.47M | 47.24M | — | 37.93M | 35.44M | 35.27M | — | 34.86M | 10.67M | 2.05M | — | 1.53M |
| EBITDA | -60.59M | -23.99M | -38.24M | -29.73M | -29.24M | -26.86M | -23.26M | -21.42M | -20.59M | -16.94M | -14.74M | -9.54M |
| Operating Margin | — | -121.07% | — | — | — | — | — | — | — | — | — | — |
| Net Margin | — | -99.28% | — | — | — | — | — | — | — | — | — | — |
This table shows 12 quarterly periods of Rapport Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow RAPP's reporting calendar. What is a income statement?